VIRAL HEPATITIS

Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy ................................................. 14:28-oa

Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C ............................................. 14:36-oa

Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis .......................... 14:46-oa

Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin ....................... 14:132-cre

Acute hepatitis E virus infection and association with a subacute thyroiditis ................................................................. 14:141-le

Pathophysiological and pharmacological implications of elucidating the molecular bases of the interaction between HBV and the bile acid transporter NTCP ........................................ 14:143-ine

The efficacy and safety of entecavir in patients with chronic hepatitis B-associated liver failure: a meta-analysis .................................. 14:150-cre

Prospective study of hepatitis B virus reactivation in patients with hematological malignancies ................................................. 14:168-ao

LAM add-on ADV combination therapy or ETV monotherapy for CHB patients with suboptimal response to ADV ..................................... 14:175-ao

Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis ..................... 14:181-ao

The fatigue impact scale for daily use in patients with hepatitis B virus and hepatitis C virus chronic infections ...................................... 14:310-oa

Does hepatitis B virus coinfection have any impact on treatment outcome in hepatitis C patients on hemodialysis? ............................. 14:317-oa

HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? .......................................................... 14:325-oa

Inter and intrapatient evolution of hepatitis C virus ........................................ 14:442-cre

The function of MicroRNA in hepatitis B virus-related liver diseases: from Dim to Bright .................................................. 14:450-cre

Hypovitaminosis D and its relation to demographic and laboratory data among hepatitis C patients ................................................. 14:457-oa

Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients .............................................. 14:464-ao

Detection of hepatitis B activity in HBeAg-negative carriers with normal aminotransferase levels in central Brazil .......................... 14:470-ao

HEPATOCELLULAR CARCINOMA

Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study .................. 14:58-oa

Wnt/β-catenin signaling pathway in hepatocellular carcinomas cases from Colombia ........................................ 14:64-oa

Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration .......................... 14:75-oa

The impact of sphingosine kinase 1 on the prognosis of hepatocellular carcinoma patients with portal vein tumor thrombus .................. 14:198-ao

Transarterial chemoembolisation in intermediate-stage hepatocellular carcinoma. Survey on clinical practice in hospitals in the Madrid Region ........................................ 14:207-oa

Comparison of two chemical models to induce hepatic preneoplasia in male Wistar rats ........................................ 14:259-ao

Obesity as a cause of hepatocellular carcinoma ........................................ 14:299-cre

Diagnosis of liver nodules within and outside screening programs .................................................................................. 14:304-ao

The ability of 17β-estradiol to attenuate intrahepatic vasoconstriction to endothelin-1 in female rats is lost in cirrhosis ................ 14:404-ao

DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma .......................... 14:494-ao

High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain .......... 14:477-oa

Liver-specific case fatality due to chronic hepatitis C virus infection: a systematic review ............................................. 14:618-cre

Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico .................................. 14:642-oa

Intermediate fibrosis staging in hepatitis C: a problem not overcome by optimal samples or pathologists' expertise ......................... 14:652-ao

Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma ........................................ 14:756-ao

Meeting the Eastern perspective in hepatitis B related ACLF .................................................................................. 14:777-ed

Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America .......................... 14:807-cre

Prevalence of hepatitis B and C markers in a population of an urban university in Rio de Janeiro, Brazil: a cross-sectional study ........... 14:815-ao

Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B .......... 14:826-ao

SUBJECT INDEX

VOLUME 14, 2015
A simple diagnostic index comprising epithelial membrane antigen and fibronectin for hepatocellular carcinoma ........................................ 14:869-oa
Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas ........................................ 14:881-oa

**LIVER CIRRHOSIS AND ITS’ COMPLICATION**

Portal vein thrombosis: What is new? ................................ 14:20-cre
The performance of prognostic models as predictors of mortality in patients with acute decompensation of cirrhosis ................................ 14:83-oa
Thrombosis and hemorrhage in the critically ill cirrhotic patients: five years retrospective prevalence study ................................ 14:93-oa
Factors associated with 25-hydroxyvitamin D levels in patients with liver cirrhosis ........................................ 14:99-oa
Paradoxical embolization in TIPS: take a closer look to the heart ................................ 14:127-cr
Enterococcus casseliflavus and Enterococcus gallinarum as causative agents of spontaneous bacterial peritonitis ................................ 14:270-cr
Clinical characteristics, predictors, and survival among patients with hepatopulmonary syndrome ................................ 14:354-oa
Exercise capacity of cirrhotic patients with hepatopulmonary syndrome ........................................ 14:361-oa
MELD score for prediction of survival after emergent TIPS for acute variceal hemorrhage: derivation and validation in a 101-patient cohort ................................ 14:380-oa
The ability of 17β-estradiol to attenuate intrahepatic vasoconstriction to endothelin-1 in female rats that is lost in cirrhosis ................................ 14:404-oa
Fecal transplant to mitigate hyperammonemia and hepatic encephalopathy in animal models ........................................ 14:762-le
The treatment of diabetes mellitus of patients with chronic liver disease ........................................ 14:780-cre
Evaluation the value of markers for prediction of portal vein thrombosis after devascularization ........................................ 14:856-oa
The burden of cirrhosis and impact of universal coverage public health care system in Thailand: Nationwide study ........................................ 14:862-oa
Peritoneal ultrafiltration for refractory fluid overload and ascites due to pulmonary arterial hypertension ........................................ 14:929-cr

**LIVER TRANSPLANTATION**

First confirmed case of native polyomavirus BK nephropathy in a liver transplant recipient seven years post-transplant ........................................ 14:137-cr
Involvement of the receptor for advanced glycation end products in liver transplantation ........................................ 14:190-oa
Liver allografts from donors with peritoneal contamination: report of two cases ........................................ 14:281-cr
Risk factors for early repeat ERCP in liver transplantation patients with anastomotic biliary stricture ........................................ 14:340-oa
Comorbidities have a limited impact on post-transplant survival in carefully selected cirrhotic patients: a population-based cohort study ........................................ 14:348-oa
Transient hyperglycemia during liver transplantation does not affect the early graft function ........................................ 14:404-oa
Risk factors for acute kidney injury and 30-day mortality after liver transplantation ........................................ 14:482-oa
Predicting early discharge from hospital after liver transplantation (ERDALT) at a single center: a new model ........................................ 14:505-oa
Assessing risk factors of acute kidney injury after liver transplantation ........................................ 14:521-oa
Acute kidney injury after liver transplantation is associated with viral hepatitis, prolonged warm ischemia, lactate and higher mortality ........................................ 14:547-ih

**MISCELLANEOUS**

Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry ........................................ 14:215-ih
Obstructive jaundice caused by a giant non-parasitic hepatic cyst ........................................ 14:267-ih
Serum ferritin is a biomarker for liver mortality in the Hemochromatosis and Iron Overload Screening Study ........................................ 14:348-oa
Safety and efficacy of angiographic occlusion of duodenal varices as an alternative to TIPS: review of 32 cases ........................................ 14:369-oa
Influence of ApoE and FABP2 polymorphisms and environmental factors in the susceptibility to gallstone disease ........................................ 14:515-oa
Multiple liver lesions in a patient with Budd-Chiari syndrome secondary to polycythemia vera ........................................ 14:547-ih
Spontaneous hepatic rupture during pregnancy in a patient with peliosis hepatis ........................................ 14:553-cre
Giant hepatocellular adenoma in a previously obese thirteen-year-old boy ........................................ 14:559-cre
Gallstone disease and obesity: a population-based study on abdominal fat distribution and gender differences ........................................ 14:702-oa
Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19 ........................................ 14:710-oa
Association of a novel TAS2R38 haplotype with alcohol intake among Mexican-Mestizo population .......... 14:729-oa
Swallowed chicken bone migration into the liver ............. 14:744-ih
Pearls for optimizing biomedical manuscripts .............. 14:774-ed
Drug-induced fatty liver disease:
An overview of pathogenesis and management ............ 14:789-cre
Drug-induced liver injury in hospitalized HIV patients: high incidence and
association with drugs for tuberculosis .................... 14:888-oa
Contrast-induced acute kidney injury in cirrhotic patients. A retrospective analysis .................. 14:895-cre
The limited prognostic value of liver histology in children with biliary atresia ........ 14:902-oa
Maternal separation on the ethanol-prefering adult rat liver structure ................ 14:910-cre
Isolated liver disease in a patient with a CFTR genotype F508del/12TGT-5 and 470MV:
A new face of an old disease ................................ 14:933-cr

NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Effects of a low-fat diet on the hepatic expression of adiponectin and its receptors in rats with NAFLD ......................... 14:108-oa
Lifestyle changes associated with a new antioxidant formulation in non-alcoholic fatty liver disease: a case series ......................... 14:121-cr
Granulocyte-colony stimulating factor prevents the development of hepatic steatosis in rats ...... 14:243-oa
The role of small heterodimer partner in hepatic lipid homeostasis .................... 14:286-lne
Impact of H63D mutations, magnetic resonance and metabolic syndrome among outpatient referrals for elevated serum ferritin in the Basque Country .................. 14:333-oa
Obeticholic acid: expanding the therapeutic landscape of NASH .................. 14:430-lne
The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease ............... 14:487-oa
Combined high-fat diet and sustained high sucrose consumption promotes NAFLD in a murine model .. 14:540-oa
Insights in non-alcoholic fatty liver disease pathophysiology with lipidomic analyses .................. 14:567-lne
Fatty liver and abdominal fat relationships with high C-reactive protein in adults without coronary heart disease .................. 14:658-cre
SFRP5 hepatic expression is associated with non-alcoholic liver disease in morbidly obese women ................. 14:666-oa

LIVER FAILURE

Traditional Chinese Medicine and herbal hepatotoxicity: a tabular compilation of reported cases .................. 14:7-cre
Usefulness of serum thyroid-stimulation hormone (TSH) as a prognostic indicator for acute-on-chronic liver failure .................. 14:218-cre
Liver-specific case fatality due to chronic hepatitis C virus infection: a systematic review .. 14:618-cre
Granulocyte-colony stimulating factor for acute-on-chronic liver failure: systematic review and meta-analysis .................. 14:631-cre
Etiology, outcome and prognostic factors of childhood acute liver failure in a German Single Center .... 14:722-cre
Gastrointestinal neuroendocrine tumor with unresectable liver metastases: an example of multimodal therapeutic approach .................. 14:752-cr

HEPATOBILIARY MALIGNANCIES

The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis .... 14:161-cre
Papillary in situ and intramucosal adenocarcinoma of the lower third of common bile duct. A report and review of the literature .................. 14:425-cre
Management of liver metastases of gastrointestinal stromal tumors (GIST) .................. 14:531-cre

AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE

Cutaneous amyloidosis associated with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome ............................................. 14:416-cr

Successful pregnancy after ileal exclusion in progressive familial intrahepatic cholestasis type 2 .......... 14:550-cr

Colorectal cancer surveillance in primary sclerosing cholangitis and inflammatory bowel disease ....................... 14:564-le

Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3 ................................. 14:745-cr

Severe hypercholesterolemia mediated by lipoprotein X in a patient with cholestasis ....................... 14:924-cr

**LIVER FIBROSIS**

Prevalence in vulnerable population of liver fibrosis identified by transient elastography ........... 14:524-oa

**HEPATITIS**

Fibro-check: a combination of direct and indirect markers for liver fibrosis staging in chronic hepatitis C patients ................................. 14:225-oa

Reasons for HCV non-treatment in underserved African Americans: Implications for treatment with new therapeutics ........... 14:234-oa

IFNL3 polymorphisms and HCV infection in patients with beta thalassemia ............................ 14:389-oa

Mycophenolic acid induces apoptosis of hepatic stellate cells in an *in vitro* model of HCV .............. 14:396-oa

Black hairy tongue during interferon therapy for hepatitis C ........................................... 14:414-ih

**LIVER HEPATITIS**

Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism ................ 14:420-cr